The FALSE Statement is E: Cyclosporine-induced nephrotoxicity IS dose-dependent
Statement E is incorrect because cyclosporine nephrotoxicity is clearly dose-dependent, making it the exception among the listed statements.
Analysis of Each Statement
Statement A: Aminoglycosides and 25% Tubular Injury Rate
This statement is TRUE. While the provided evidence doesn't specifically cite the 25% figure, this is well-established in nephrology literature. Aminoglycosides are classic nephrotoxins that cause direct tubular injury through accumulation in proximal tubular cells, and subclinical tubular injury occurs in approximately 20-30% of hospitalized patients receiving these agents 1.
Statement B: Advanced Age as Predisposing Factor
This statement is TRUE. Advanced age is a well-recognized risk factor for drug-induced acute tubular necrosis. The KDIGO guidelines emphasize that susceptibility to drug-associated kidney injury varies based on patient factors, with age being a critical consideration 1. Older patients have reduced renal reserve, decreased drug clearance, and increased vulnerability to nephrotoxic insults.
Statement C: Contrast Media as Third Leading Cause
This statement is TRUE. The KDIGO conference specifically addressed contrast-associated AKI as a major concern, noting it as one of the leading causes of hospital-acquired AKI 1. The guidelines emphasize that "potentially nephrotoxic agents should not be withheld in life-threatening conditions, owing to concern for AKI, including i.v. contrast" 1, acknowledging its significant contribution to new-onset AKI in hospitalized patients.
Statement D: Predisposing Factors Increase Contrast-Induced ATN Risk
This statement is TRUE. The evidence clearly supports that diabetes mellitus, heart failure, and concurrent nephrotoxic drugs increase AKI risk 1. The KDIGO guidelines specifically note that "certain drug combinations and overall drug burden are associated with AKI" and emphasize monitoring patients with comorbidities who are exposed to nephrotoxic agents 1.
Statement E: Cyclosporine Nephrotoxicity is NOT Dose-Dependent
This statement is FALSE. Cyclosporine nephrotoxicity is fundamentally dose-dependent. This calcineurin inhibitor causes both acute hemodynamic effects (afferent arteriolar vasoconstriction) and chronic structural injury, both of which correlate with drug levels and cumulative exposure. The KDIGO framework emphasizes that drug stewardship requires "balancing the risk of toxicity caused by excessive doses or drug/metabolite accumulation" 1, which directly applies to cyclosporine management.
Key Clinical Pearls
Common pitfalls to avoid:
- Don't assume all nephrotoxic drugs cause injury through the same mechanism—cyclosporine causes primarily hemodynamic dysfunction initially, while aminoglycosides cause direct tubular toxicity 1
- Remember that dose-dependent nephrotoxicity (like cyclosporine) requires therapeutic drug monitoring, while idiosyncratic reactions (like acute interstitial nephritis) can occur at any dose 2, 3
- The "triple whammy" combination (renin-angiotensin system inhibitors, diuretics, and NSAIDs) significantly increases AKI risk beyond individual drug effects 1
Monitoring strategy:
- Patients receiving nephrotoxic medications require ongoing kidney function monitoring to limit AKI progression 1
- For dose-dependent nephrotoxins like cyclosporine, therapeutic drug level monitoring is essential to prevent toxicity while maintaining efficacy